|
|
5-day change | 1st Jan Change | ||
|
1.690 AUD |
+5.62% | +12.67% | +64.88% | |
April 13, 2025 at 08:03 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
EBR Systems Says US FDA Approval for Wireless Cardiac Therapy System Nears |
Mar. 24 |
MT |
|
EBR Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 24 |
CI |
|
EBR Systems, Inc.(ASX:EBR) added to S&P/ASX Emerging Companies Index |
Mar. 23 |
CI |
|
EBR Systems Secures 11-Year Lease Deal for Commercial Facility; Shares Up 4% |
Jan. 27 |
MT |
|
Global markets live: Chevron, Amazon, GSK, Intel, Zalando… |
Jan. 20 |
 |
|
EBR Systems’ Wireless Pacing System Gets Accepted into US Reimbursement Pathway; Shares Reach All-Time High |
Jan. 19 |
MT |
|
EBR Systems Says US FDA Completes Pre-Approval Inspection; Shares Hit All-Time High |
Jan. 19 |
MT |
|
EBR Systems Says US FDA Updated Manufacturing Pre-Approval Inspection Schedule; Shares Reach All-Time High |
Jan. 05 |
MT |
|
EBR Systems’ US FDA Pre-Approval Inspection Set for January 2025; Shares Up 3% |
Dec. 18 |
MT |
|
EBR Systems to Meet with US FDA for Cardiac Pacing Device Application; Shares Up 5% |
Dec. 05 |
MT |
|
EBR Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 12 |
CI |
|
EBR Systems Submits NTAP Application for Heart Pacing System; Shares Up 5% |
24-10-15 |
MT |
|
EBR Systems Raises Over AU$3 Million via Retail Entitlement Offer; Shares Up 4% |
24-10-13 |
MT |
|
US FDA Accepts EBR Systems’ Pre-Market Application for Heart Pacing System |
24-09-29 |
MT |
|
EBR Systems Completes AU$45.8 Million Raise |
24-09-19 |
MT |
|
EBR Systems Files Final Module with US FDA for Cardiac Therapy System |
24-08-28 |
MT |
|
EBR Systems, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024 |
24-08-26 |
CI |
|
Australian Shares Fall on Fading Rate Cut Hopes; BHP Slips 4% on Anglo American Bid Update |
24-04-26 |
MT |
|
EBR Systems on Track to Submit Cardiac Pacing Technology’s Final Module to US FDA in Q3 |
24-04-26 |
MT |
|
EBR Systems, Inc.(ASX:EBR) added to S&P/ASX All Ordinaries Index |
24-03-17 |
CI |
|
EBR Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 |
24-02-27 |
CI |
|
1,104,030 Warrants of EBR Systems, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. |
23-11-23 |
CI |
|
11,546,742 Options of EBR Systems, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. |
23-11-23 |
CI |
|
5,785,188 CHESS Depositary Interests of EBR Systems, Inc. are subject to a Lock-Up Agreement Ending on 24-NOV-2023. |
23-11-23 |
CI |
|
EBR Systems, Inc. Announces Positive Results from First-In-Human Fully Leadless CRT in the US, Published in the Journal of the American College of Cardiology |
23-10-25 |
CI |
EBR: Dynamic Chart
EBR Systems, Inc. is engaged in the treatment of patients suffering from cardiac rhythm diseases by providing physiological stimulation through endocardial pacing. It is a medical device company developing the wireless stimulation endocardially cardiac resynchronization therapy (WiSE CRT) System, an implantable cardiac pacing system that stimulates endocardial heart tissue to correct heart rhythm conditions without using leads. This investigational device delivers left-ventricle endocardial pacing for CRT without wires or leads. The WiSE CRT System developed a new approach to cardiac pacing, aiming to transform CRT delivery and benefit patients who have not succeeded with conventional CRT. It operates wholly owned subsidiaries in Australia (EBR Systems (AUST) Pty Ltd) and the United Kingdom (EBR Systems (UK) Limited), which conduct clinical trials and work on intellectual property development in their respective regions.
More about the company
Buy
Average target price
1.726USD
Spread / Average Target
+64.08%
Consensus
Quarterly revenue – Rate of surprise
}
